Measurement of the 177Lu half-life

Activity standardization and half-life measurement of 177Lu

The activity of the ¹⁷⁷Lu solution has been measured by means of the CIEMAT/NIST efficiency tracing method. This result has been compared to the previous obtained results received from 4πβ(LS)-γ coincidence and anticoincidence counting. The activities determined with various methods have been found to be consistent. The decay curve of the ¹⁷⁷Lu solution has been followed in the TDCR counter to determine the half-life of this isotope. The half-life has been separately determined for double and triple coincidence events. The arithmetic mean value of these two results has been found to be T_1/2 = 6.6489(52) d.

Radionuclide metrology: confidence in radioactivity measurements

Radionuclides, whether naturally occurring or artificially produced, are readily detected through their particle and photon emissions following nuclear decay. Radioanalytical techniques use the radiation as a looking glass into the composition of materials, thus providing valuable information to various scientific disciplines. Absolute quantification of the measurand often relies on accurate knowledge of nuclear decay data and detector calibrations traceable to the SI units. Behind the scenes of the radioanalytical world, there is a small community of radionuclide metrologists who provide the vital tools to convert detection rates into activity values. They perform highly accurate primary standardisations of activity to establish the SI-derived unit becquerel for the most relevant radionuclides, and demonstrate international equivalence of their standards through key comparisons. The trustworthiness of their metrological work crucially depends on painstaking scrutiny of their methods and the elaboration of comprehensive uncertainty budgets. Through meticulous methodology, rigorous data analysis, performance of reference measurements, technological innovation, education and training, and organisation of proficiency tests, they help the user community to achieve confidence in measurements for policy support, science, and trade. The author dedicates the George Hevesy Medal Award 2020 to the current and previous generations of radionuclide metrologists who have devoted their professional lives to this noble endeavour.

Radioisotope production at the IFMIF-DONES facility

The International Fusion Materials Irradiation Facility - Demo Oriented NEutron Source (IFMIF-DONES) is a single-sited novel Research Infrastructure for testing, validation and qualification of the materials to be used in a fusion reactor. Recently, IFMIF-DONES has been declared of interest by ESFRI (European Strategy Forum on Research Infrastructures) and its European host city would be Granada (Spain). In spite the first and most important application of IFMIF-DONES related to fusion technology, the unprecedented neutron flux available could be exploited without modifying the routine operation of IFMIF-DONES. Thus, it is already planned an experimental hall for a complementary program with neutrons. Also, a complementary program on the use of the deuteron beam could help IFMIF-DONES to be more sustainable. In the present work, we study radioisotope production with deuterons of 177Lu. The results show the viability of IFMIF-DONES for such production in terms of the needs of a territory of small-medium size. Also the study suggests that new nuclear data at higher deuteron energies are mandatory for an accurate study in this field.

Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions

Bone pain arising from secondary skeletal malignancy constitutes one of the most common types of chronic pain among patients with cancer which can lead to rapid deterioration of the quality of life. Radionuclide therapy using bone-seeking radiopharmaceuticals based on the concept of localization of the agent at bone metastases sites to deliver focal cytotoxic levels of radiation emerged as an effective treatment modality for the palliation of symptomatic bone metastases. Bone-seeking radiopharmaceuticals not only provide palliative benefit but also improve clinical outcomes in terms of overall and progression-free survival. There is a steadily expanding list of therapeutic radionuclides which are used or can potentially be used in either ionic form or in combination with carrier molecules for the management of bone metastases. This article offers a narrative review of the armamentarium of bone-targeting radiopharmaceuticals based on currently approved investigational and potentially useful radionuclides and examines their efficacy for the treatment of painful skeletal metastases. In addition, the article also highlights the processes, opportunities, and challenges involved in the development of bone-seeking radiopharmaceuticals. Radium-223 is the first agent in this class to show an overall survival advantage in Castration-Resistant Prostate Cancer (CRPC) patients with bone metastases. This review summarizes recent advances, current clinical practice using radiopharmaceuticals for bone pain palliation, and the expected future prospects in this field.

Linearity check of an ionisation chamber through 99 mTc half-life measurements

The half-life of ^99 mTc was measured at the JRC using the ionisation chamber 'IC1' (type Centronic IG12). The result, T_1/2(^99 mTc) = 6.00660 (18) h, is in good agreement with literature data. One experiment was performed in IC1's default set-up with the ionisation current being integrated over an air capacitor and read out as a voltage increase over time. This ensured excellent linearity and precision throughout the dynamic range, but the maximum current was limited to 2 nA. In a second test, the current was directly read out with a Keithley 6517 A electrometer. Applying correction factors for the automatic range switching of the electrometer, an acceptable linearity was demonstrated over a range of 12 half-life periods starting at 20 nA. Range switching and autocorrelation of the current readout increase the systematic and random error propagation factors. Piecewise fitting of the decay curve over periods of 6 h yields the same ^99 mTc half-life value within 0.04% (0.0025 h) standard deviation over an activity range spanning at least 10 half-life periods (3 orders of magnitude).

Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at risk

PURPOSE

Peptide receptor radionuclide therapy (PRRT) has shown promising results in the treatment of tumors with high expression of somatostatin receptors such as neuroendocrine tumors (NETs) and meningioma. However, PRRT potentially produces high renal and red marrow (RM) toxicity, the kidneys usually being the dose-limiting organ. Previously, it was shown that an improved therapeutic index can be achieved by choosing an optimal combination of injected activity and peptide molar amount. The aim of this work was to develop a clinically applicable algorithm for treatment planning in PRRT. To demonstrate the applicability and possible advantages of the algorithm thus developed, an in silico clinical trial applying the algorithm to 177 Lu-DOTATATE therapy in nine virtual patients was conducted.

METHODS

An algorithm for treatment planning in PRRT was developed, which simultaneously considers multiple tumor lesions, maximum tolerated biologically effective doses (BEDs) for multiple organs at risk (OARs) and a maximum achievable molar activity. The algorithm, subject to the abovementioned constraints, aims at maximizing the total number of killed tumor cells in the considered lesions/metastases. An in silico clinical trial was conducted with nine virtual patients. For each virtual patient, simulations increasing the molar dose of 177 Lu-DOTATATE from 2 to 2048 nmol by factors of 25 were performed. Maximum tolerated BEDs per cycle for the kidneys (10 Gy2.5 ) and for the RM (0.5 Gy15 ) were defined based on a planned total treatment of four cycles. A maximum achievable molar activity of 420 MBq/nmol was assumed. Optimal combinations of molar dose and activity were determined by applying the developed algorithm. For comparison, simulations for a typical plan with 177 Lu-DOTATATE (7.4 GBq, 265 nmol) were performed and BEDs for the OARs and for individual tumor lesions were calculated. Furthermore, to determine treatment efficacy, overall tumor control probability (oTCP) values after a four-cycle treatment were estimated for the optimal and typical plans.

RESULTS

The conducted in silico clinical trial yielded optimal molar doses and activities ranging from 24 to 512 nmol and from 6 to 30 GBq, respectively. Tumor BEDs ranged from 2 to 107 Gy10 and from 1 to 65 Gy10 for the optimal and typical plans, respectively. The estimated oTCP values showed that the optimal plans may produce adequate tumor control in six of the nine virtual patients after four cycles of 177 Lu-DOTATATE while the typical plan may be sufficient in only two virtual patients.

CONCLUSIONS

The algorithm presented can derive plans with higher tumor control than the typically delivered plan. Therefore, we propose this algorithm for clinical validation and possibly future implementation in treatment planning in molecular radiotherapy.

(177)Lu: DDEP Evaluation of the decay scheme for an emerging radiopharmaceutical

A new decay scheme evaluation using the DDEP methodology for (177)Lu is presented. Recently measured half-life measurements have been incorporated, as well as newly available γ-ray emission probabilities. For the first time, a thorough investigation has been made of the γ-ray multipolarities. The complete data tables and detailed evaluator comments are available through the DDEP website.

Metastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid

¹⁷⁷Lu-ethylenediaminetetramethylene phosphonic acid (EDTMP) is presently suggested as an excellent bone seeking radionuclide for developing metastatic bone pain (MBP) palliation agent owing to its suitable nuclear decay characteristics. To find the exact dosage and its efficiency, this clinical study was performed on the human being, using ¹⁷⁷Lu-EDTMP for MBP palliation. ¹⁷⁷Lu-EDTMP was prepared by Iran, atomic energy organization. Thirty consecutive patients with determined tumors, incontrollable MBP, and positive bone scan at 4 weeks before the beginning of the study participated in this study in the nuclear medicine ward. ¹⁷⁷Lu-EDTMP in the form of sterile slow IV injection was administered with a dose of 29.6 MBq/kg. Short form of brief pain inventory questionnaire was used to evaluate the efficiency of the intervention. Questionnaires were filled out by an expert nuclear physician every 2 weeks while the cell blood count was also checked every 2 weeks up to 12 weeks for evaluation of bone marrow suppression and hematological toxicity. Furthermore, whole body scan was done at days 1, 3, and 7. Twenty-five patients showed a significant pain relief since 2 weeks after the injection, and continued until the end of the follow up period (12 weeks). There were no significant early complications such as bone marrow suppression, hematological toxicity, and no systemic adverse effects. No complication was observed in renal function. Twenty one patients showed flare phenomenon that was started after the 12.2 ± 1.78 h lasting for 38.4 ± 23.08. Sixteen patients (53%) were completely treated; nine patients (30%) showed a partial response, and five patients (17%) had no response to treatment. Total response to treatment was achieved in 25 patients (83%). At the end of the evaluation, no bone marrow suppression or hematologic toxicity was observed. ¹⁷⁷Lu-EDTMP has shown suitable physical and biological properties with good results in long term bone pain relief for patients with bone metastasis.

Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series

The half-lives of (221)Fr, (217)At, (213)Bi, (213)Po, and (209)Pb were measured by means of an ion-implanted planar Si detector for alpha and beta particles emitted from weak (225)Ac sources or from recoil sources, which were placed in a quasi-2π counting geometry. Recoil sources were prepared by collecting atoms from an open (225)Ac source onto a glass substrate. The (221)Fr and (213)Bi half-lives were determined by following the alpha particle emission rate of recoil sources as a function of time. Similarly, the (209)Pb half-life was determined from the beta particle count rate. The shorter half-lives of (217)At and (213)Po were deduced from delayed coincidence measurements on weak (225)Ac sources using digital data acquisition in list mode. The resulting values: T1/2((221)Fr)=4.806 (6) min, T1/2((217)At)=32.8 (3)ms, T1/2((213)Bi)=45.62 (6)min, T1/2((213)Po)=3.708 (8) μs, and T1/2((209)Pb)=3.232 (5)h were in agreement only with the best literature data.

Measurement of the 225Ac half-life

The (225)Ac half-life was determined by measuring the activity of (225)Ac sources as a function of time, using various detection techniques: α-particle counting with a planar silicon detector at a defined small solid angle and in a nearly-2π geometry, 4πα+β counting with a windowless CsI sandwich spectrometer and with a pressurised proportional counter, gamma-ray spectrometry with a HPGe detector and with a NaI(Tl) well detector. Depending on the technique, the decay was followed for 59-141 d, which is about 6-14 times the (225)Ac half-life. The six measurement results were in good mutual agreement and their mean value is T(1/2)((225)Ac)=9.920 (3)d. This half-life value is more precise and better documented than the currently recommended value of 10.0 d, based on two old measurements lacking uncertainty evaluations.

57Co half-life determination

The National Laboratory for Metrology of Ionizing Radiation (LNMRI)/Brazil participated in the last (57)Co activity measurement comparison organized by IAEA, in 2008. This was made in order to realize primary standardization of this radionuclide and to reduce the measuring uncertainties in the laboratory. Additionally, one sample with 2.6g was taken from the IAEA master solution of (57)Co and was prepared to be used in the measurement of the radionuclide's half-life in an ionization chamber system. The (57)Co half-life was measured to be 271.82 (17) days.